There's a growing recognition that the molecular profile of a primary tumor can differ significantly from its metastases. To guide treatment more accurately, the preferred practice is to biopsy an accessible metastatic lesion when possible, as this better reflects the biology of the active disease being treated.

Emerging data indicates that Tarlatamab, a DLL3-targeted therapy, has inferior performance in small cell lung cancer (SCLC) that transformed from EGFR-mutant NSCLC compared to its efficacy in de novo SCLC. This suggests the biological context of transformation impacts treatment response, a critical nuance for this new therapy.

When a liquid biopsy fails to detect the original EGFR driver mutation in a patient progressing on therapy, it should not be interpreted as the cancer losing its dependency. This result more likely indicates insufficient tumor DNA shedding, signaling that the test is uninformative and a tissue biopsy is needed.

While liquid biopsies are a valuable, less invasive tool, a negative result is inconclusive for ruling out actionable mutations in NSCLC. It may simply mean the tumor isn't shedding enough DNA. Therefore, a negative liquid biopsy should never be the final word; it must be followed by a tissue biopsy to ensure patients don't miss out on targeted therapies.

A case study reveals the remarkable plasticity of EGFR-mutated lung cancer. After transforming from adenocarcinoma to small cell histology and receiving treatment, a subsequent biopsy showed it had reverted to adenocarcinoma. This highlights extreme tumor heterogeneity and the need for repeat biopsies upon progression.

When patients with EGFR-mutated lung cancer progress on osimertinib, a re-biopsy is essential not just for new genomic markers. It's critical for identifying histologic transformation to small cell or squamous cell cancer, which mandates a complete switch to chemotherapy-based regimens.

Patients with EGFR-mutant NSCLC that transforms into small cell lung cancer show poor responses to new therapies like tarlatamab, which are highly effective in de novo small cell cancer. This highlights a distinct biology that requires different therapeutic strategies and dedicated clinical trials.

When EGFR+ NSCLC transforms to small cell, clinicians often continue the TKI osimertinib alongside chemotherapy. This practice is largely based on expert consensus and the rationale of suppressing any remaining EGFR-driven clones, rather than on definitive clinical trial data showing a clear benefit.

Contrary to its traditional monolithic treatment approach, SCLC is now understood to have distinct transcriptomic subsets (e.g., ASCL1, NeuroD1). The future of SCLC therapy will likely involve biomarker testing to match patients with the most effective treatments for their specific subtype, mirroring the personalized approach in non-small cell lung cancer.